Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2–3 Months Post ABMT View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1990

AUTHORS

D. Maraninchi , D. Blaise , D. Olive , M. Attal , M. H. Gaspard , D. Boule , C. Jasmin , C. Pourreau , P. Palmer , S. Négrier , I. Philip

ABSTRACT

Association of high-dose radiotherapy ± chemotherapy can cure poor risk hematological neoplasias and solid tumors. This cure is related to the treatment dose effect as well as to the immunological effect (graft versus tumor effect) demonstrated after bone marrow transplant (BMT). Relapses are less frequent after allogeneic BMT than after autologous or syngeneic transplant; they are also less frequent following graft-versus-host disease (GVHD) in allogeneic transplantation (graft versus leukemia (GVL) effect). T cell depletion increases the risk of relapses [2]. The use of recombinant interleukine-2 (rIL-2) is under intensive investigation since promising reports have shown high activity in patients with refractory neoplasias [3]. T lymphocytes with antileukemic activity can be expanded from the blood of patients with leukemia [1]. Use of rIL-2 after autologous transplant may enhance immunologic abnormalities already documented e.g., CD4()CD8 inversion, increase in activated T cells and natural killer (NK) cells, and by this way increase antitumoral activated. This study is a phase 1 study to detemine feasability of rIL-2 administration 60-90 days post-autologous BMT. More... »

PAGES

691-697

Book

TITLE

Cytokines in Hemopoiesis, Oncology, and AIDS

ISBN

978-3-540-52281-2
978-3-642-75510-1

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-642-75510-1_87

DOI

http://dx.doi.org/10.1007/978-3-642-75510-1_87

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1021751869


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "familyName": "Maraninchi", 
        "givenName": "D.", 
        "id": "sg:person.01364057057.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364057057.31"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Blaise", 
        "givenName": "D.", 
        "id": "sg:person.0644473065.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644473065.59"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Olive", 
        "givenName": "D.", 
        "id": "sg:person.0622550070.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622550070.07"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Attal", 
        "givenName": "M.", 
        "id": "sg:person.01355527565.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355527565.13"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Gaspard", 
        "givenName": "M. H.", 
        "id": "sg:person.0634547675.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634547675.86"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Boule", 
        "givenName": "D.", 
        "type": "Person"
      }, 
      {
        "familyName": "Jasmin", 
        "givenName": "C.", 
        "id": "sg:person.01120567767.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120567767.26"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Pourreau", 
        "givenName": "C.", 
        "id": "sg:person.01134434522.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134434522.91"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Palmer", 
        "givenName": "P.", 
        "id": "sg:person.01345034754.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345034754.91"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "N\u00e9grier", 
        "givenName": "S.", 
        "id": "sg:person.0723756046.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Philip", 
        "givenName": "I.", 
        "id": "sg:person.0725534606.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725534606.74"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1990", 
    "datePublishedReg": "1990-01-01", 
    "description": "Association of high-dose radiotherapy \u00b1 chemotherapy can cure poor risk hematological neoplasias and solid tumors. This cure is related to the treatment dose effect as well as to the immunological effect (graft versus tumor effect) demonstrated after bone marrow transplant (BMT). Relapses are less frequent after allogeneic BMT than after autologous or syngeneic transplant; they are also less frequent following graft-versus-host disease (GVHD) in allogeneic transplantation (graft versus leukemia (GVL) effect). T cell depletion increases the risk of relapses [2]. The use of recombinant interleukine-2 (rIL-2) is under intensive investigation since promising reports have shown high activity in patients with refractory neoplasias [3]. T lymphocytes with antileukemic activity can be expanded from the blood of patients with leukemia [1]. Use of rIL-2 after autologous transplant may enhance immunologic abnormalities already documented e.g., CD4()CD8 inversion, increase in activated T cells and natural killer (NK) cells, and by this way increase antitumoral activated. This study is a phase 1 study to detemine feasability of rIL-2 administration 60-90 days post-autologous BMT.", 
    "editor": [
      {
        "familyName": "Freund", 
        "givenName": "Mathias", 
        "type": "Person"
      }, 
      {
        "familyName": "Link", 
        "givenName": "Hartmut", 
        "type": "Person"
      }, 
      {
        "familyName": "Welte", 
        "givenName": "Karl", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-642-75510-1_87", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-540-52281-2", 
        "978-3-642-75510-1"
      ], 
      "name": "Cytokines in Hemopoiesis, Oncology, and AIDS", 
      "type": "Book"
    }, 
    "keywords": [
      "bone marrow transplantation", 
      "interleukin-2", 
      "post autologous bone marrow transplantation", 
      "allogeneic bone marrow transplantation", 
      "autologous bone marrow transplantation", 
      "phase 1 study", 
      "high-dose radiotherapy", 
      "natural killer cells", 
      "bone marrow transplant", 
      "risk of relapse", 
      "blood of patients", 
      "refractory neoplasia", 
      "host disease", 
      "syngeneic transplants", 
      "immunologic abnormalities", 
      "allogeneic transplantation", 
      "autologous transplant", 
      "killer cells", 
      "marrow transplantation", 
      "marrow transplant", 
      "cell depletion", 
      "rIL-2", 
      "immunological effects", 
      "late administration", 
      "solid tumors", 
      "hematological neoplasias", 
      "antileukemic activity", 
      "transplant", 
      "promising reports", 
      "pilot study", 
      "dose effect", 
      "relapse", 
      "transplantation", 
      "patients", 
      "neoplasia", 
      "cells", 
      "intensive investigation", 
      "ABMT", 
      "chemotherapy", 
      "radiotherapy", 
      "graft", 
      "lymphocytes", 
      "tumors", 
      "leukemia", 
      "abnormalities", 
      "disease", 
      "administration", 
      "blood", 
      "study", 
      "cure", 
      "risk", 
      "activity", 
      "association", 
      "report", 
      "effect", 
      "antitumoral", 
      "use", 
      "depletion", 
      "increase", 
      "high activity", 
      "investigation", 
      "feasability", 
      "inversion", 
      "poor risk hematological neoplasias", 
      "risk hematological neoplasias", 
      "treatment dose effect", 
      "way increase antitumoral", 
      "increase antitumoral", 
      "detemine feasability", 
      "rIL-2 administration 60", 
      "administration 60", 
      "days post-autologous BMT", 
      "Months Post ABMT", 
      "Post ABMT"
    ], 
    "name": "Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2\u20133 Months Post ABMT", 
    "pagination": "691-697", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1021751869"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-642-75510-1_87"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-642-75510-1_87", 
      "https://app.dimensions.ai/details/publication/pub.1021751869"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2021-12-01T20:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/chapter/chapter_392.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-642-75510-1_87"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-75510-1_87'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-75510-1_87'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-75510-1_87'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-642-75510-1_87'


 

This table displays all metadata directly associated to this object as RDF triples.

203 TRIPLES      23 PREDICATES      101 URIs      93 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-642-75510-1_87 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 anzsrc-for:1107
4 schema:author N7e57db7f7db3417fac327c462048d05c
5 schema:datePublished 1990
6 schema:datePublishedReg 1990-01-01
7 schema:description Association of high-dose radiotherapy ± chemotherapy can cure poor risk hematological neoplasias and solid tumors. This cure is related to the treatment dose effect as well as to the immunological effect (graft versus tumor effect) demonstrated after bone marrow transplant (BMT). Relapses are less frequent after allogeneic BMT than after autologous or syngeneic transplant; they are also less frequent following graft-versus-host disease (GVHD) in allogeneic transplantation (graft versus leukemia (GVL) effect). T cell depletion increases the risk of relapses [2]. The use of recombinant interleukine-2 (rIL-2) is under intensive investigation since promising reports have shown high activity in patients with refractory neoplasias [3]. T lymphocytes with antileukemic activity can be expanded from the blood of patients with leukemia [1]. Use of rIL-2 after autologous transplant may enhance immunologic abnormalities already documented e.g., CD4()CD8 inversion, increase in activated T cells and natural killer (NK) cells, and by this way increase antitumoral activated. This study is a phase 1 study to detemine feasability of rIL-2 administration 60-90 days post-autologous BMT.
8 schema:editor N1bbd8744f9d54581beea3e136921180f
9 schema:genre chapter
10 schema:inLanguage en
11 schema:isAccessibleForFree false
12 schema:isPartOf Nf1b2a5deece34cd58cdd170b1157f4a7
13 schema:keywords ABMT
14 Months Post ABMT
15 Post ABMT
16 abnormalities
17 activity
18 administration
19 administration 60
20 allogeneic bone marrow transplantation
21 allogeneic transplantation
22 antileukemic activity
23 antitumoral
24 association
25 autologous bone marrow transplantation
26 autologous transplant
27 blood
28 blood of patients
29 bone marrow transplant
30 bone marrow transplantation
31 cell depletion
32 cells
33 chemotherapy
34 cure
35 days post-autologous BMT
36 depletion
37 detemine feasability
38 disease
39 dose effect
40 effect
41 feasability
42 graft
43 hematological neoplasias
44 high activity
45 high-dose radiotherapy
46 host disease
47 immunologic abnormalities
48 immunological effects
49 increase
50 increase antitumoral
51 intensive investigation
52 interleukin-2
53 inversion
54 investigation
55 killer cells
56 late administration
57 leukemia
58 lymphocytes
59 marrow transplant
60 marrow transplantation
61 natural killer cells
62 neoplasia
63 patients
64 phase 1 study
65 pilot study
66 poor risk hematological neoplasias
67 post autologous bone marrow transplantation
68 promising reports
69 rIL-2
70 rIL-2 administration 60
71 radiotherapy
72 refractory neoplasia
73 relapse
74 report
75 risk
76 risk hematological neoplasias
77 risk of relapse
78 solid tumors
79 study
80 syngeneic transplants
81 transplant
82 transplantation
83 treatment dose effect
84 tumors
85 use
86 way increase antitumoral
87 schema:name Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2–3 Months Post ABMT
88 schema:pagination 691-697
89 schema:productId N23cf4908687342e280b40c0460e119f4
90 Nacc1dbcb08c34e1ca261201e7f24c18b
91 schema:publisher N44426e2e885e446f90dcbc24bfa74754
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021751869
93 https://doi.org/10.1007/978-3-642-75510-1_87
94 schema:sdDatePublished 2021-12-01T20:08
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Na60bb695b22c4ba3b99367dc3541000e
97 schema:url https://doi.org/10.1007/978-3-642-75510-1_87
98 sgo:license sg:explorer/license/
99 sgo:sdDataset chapters
100 rdf:type schema:Chapter
101 N1bbd8744f9d54581beea3e136921180f rdf:first Nd9b43407757a40978c08428c0bf1b5b1
102 rdf:rest Na76052b9eaf343f0aea72f58462c5315
103 N23cf4908687342e280b40c0460e119f4 schema:name doi
104 schema:value 10.1007/978-3-642-75510-1_87
105 rdf:type schema:PropertyValue
106 N34422a6687b147cc81b59fe6cc75ca41 schema:familyName Welte
107 schema:givenName Karl
108 rdf:type schema:Person
109 N35761601a37c45c381ec89f440976e96 schema:familyName Link
110 schema:givenName Hartmut
111 rdf:type schema:Person
112 N44426e2e885e446f90dcbc24bfa74754 schema:name Springer Nature
113 rdf:type schema:Organisation
114 N44d85e2f932a4637b687e1d2a17d00ef rdf:first sg:person.0622550070.07
115 rdf:rest N79d15d75ab3e4edeae8e347963b1d0d1
116 N4d8b155febad4ef8871716cb23cf018f rdf:first sg:person.01134434522.91
117 rdf:rest Nc1bd3cab28bb4ccca2456d7102b5e906
118 N6c6dce324cca46e18de0665931d0a917 rdf:first Nfea1cea6ef944c758cc9b88f89417387
119 rdf:rest Nb08e70a3af0543639b1c256c9ac61979
120 N79d15d75ab3e4edeae8e347963b1d0d1 rdf:first sg:person.01355527565.13
121 rdf:rest Nc4971d0ada8e496fa4411b55ab97aee5
122 N7e57db7f7db3417fac327c462048d05c rdf:first sg:person.01364057057.31
123 rdf:rest Ndeb7768c00cb40bcaf74aa19f2eb358e
124 N86a991b809804f8980fd1f787ca72b8c rdf:first sg:person.0725534606.74
125 rdf:rest rdf:nil
126 Na146884a897548f880d2fbdcd5e1bc41 rdf:first N34422a6687b147cc81b59fe6cc75ca41
127 rdf:rest rdf:nil
128 Na60bb695b22c4ba3b99367dc3541000e schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 Na76052b9eaf343f0aea72f58462c5315 rdf:first N35761601a37c45c381ec89f440976e96
131 rdf:rest Na146884a897548f880d2fbdcd5e1bc41
132 Nacc1dbcb08c34e1ca261201e7f24c18b schema:name dimensions_id
133 schema:value pub.1021751869
134 rdf:type schema:PropertyValue
135 Nb08e70a3af0543639b1c256c9ac61979 rdf:first sg:person.01120567767.26
136 rdf:rest N4d8b155febad4ef8871716cb23cf018f
137 Nc1bd3cab28bb4ccca2456d7102b5e906 rdf:first sg:person.01345034754.91
138 rdf:rest Nd777dcbbfdf74404bcaec2e9cf3d97c2
139 Nc4971d0ada8e496fa4411b55ab97aee5 rdf:first sg:person.0634547675.86
140 rdf:rest N6c6dce324cca46e18de0665931d0a917
141 Nd777dcbbfdf74404bcaec2e9cf3d97c2 rdf:first sg:person.0723756046.31
142 rdf:rest N86a991b809804f8980fd1f787ca72b8c
143 Nd9b43407757a40978c08428c0bf1b5b1 schema:familyName Freund
144 schema:givenName Mathias
145 rdf:type schema:Person
146 Ndeb7768c00cb40bcaf74aa19f2eb358e rdf:first sg:person.0644473065.59
147 rdf:rest N44d85e2f932a4637b687e1d2a17d00ef
148 Nf1b2a5deece34cd58cdd170b1157f4a7 schema:isbn 978-3-540-52281-2
149 978-3-642-75510-1
150 schema:name Cytokines in Hemopoiesis, Oncology, and AIDS
151 rdf:type schema:Book
152 Nfea1cea6ef944c758cc9b88f89417387 schema:familyName Boule
153 schema:givenName D.
154 rdf:type schema:Person
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
159 schema:name Cardiorespiratory Medicine and Haematology
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
162 schema:name Immunology
163 rdf:type schema:DefinedTerm
164 sg:person.01120567767.26 schema:familyName Jasmin
165 schema:givenName C.
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01120567767.26
167 rdf:type schema:Person
168 sg:person.01134434522.91 schema:familyName Pourreau
169 schema:givenName C.
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134434522.91
171 rdf:type schema:Person
172 sg:person.01345034754.91 schema:familyName Palmer
173 schema:givenName P.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345034754.91
175 rdf:type schema:Person
176 sg:person.01355527565.13 schema:familyName Attal
177 schema:givenName M.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355527565.13
179 rdf:type schema:Person
180 sg:person.01364057057.31 schema:familyName Maraninchi
181 schema:givenName D.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01364057057.31
183 rdf:type schema:Person
184 sg:person.0622550070.07 schema:familyName Olive
185 schema:givenName D.
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622550070.07
187 rdf:type schema:Person
188 sg:person.0634547675.86 schema:familyName Gaspard
189 schema:givenName M. H.
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0634547675.86
191 rdf:type schema:Person
192 sg:person.0644473065.59 schema:familyName Blaise
193 schema:givenName D.
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644473065.59
195 rdf:type schema:Person
196 sg:person.0723756046.31 schema:familyName Négrier
197 schema:givenName S.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723756046.31
199 rdf:type schema:Person
200 sg:person.0725534606.74 schema:familyName Philip
201 schema:givenName I.
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0725534606.74
203 rdf:type schema:Person
 




Preview window. Press ESC to close (or click here)


...